GlaxoSmithKline has acquired exclusive negotiating rights to pain relief product using Futura’s DermaSys technology, including presumably the diclofenac product DCF100. The move means GSK now has option rights to three Futura R&D programmes, in addition to the MED2002 erectile dysfunction treatment, which is already covered by a development deal.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here